<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Repligen Corporation

    Repligen Corporation

    Repligen Corporation is a global bioprocessing company that develops and commercia...

    Repligen Corporation is a global bioprocessing ...

    Filing Type:    PU
    Axovant Gene Therapies Ltd.

    Axovant Gene Therapies Ltd.

    Axovant is accelerating the development of innovative gene therapy products that a...

    Axovant is accelerating the development of inno...

    Filing Type:    PU
    Neurocarrus Inc

    Neurocarrus Inc

    Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...

    Neurocarrus is developing a breakthrough therap...

    Amount Raised:    $344,168.00
    Fundraising Status:    EC
    Filing Type:    CF
    Venomyx, Inc

    Venomyx, Inc

    We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...

    We're developing Vipax, the world's first porta...

    Amount Raised:    $290,122.00
    Fundraising Status:    EC
    Filing Type:    CF
    GW Pharmaceuticals Plc

    GW Pharmaceuticals Plc

    Founded in 1998, GW is a biopharmaceutical company focused on discovering, develop...

    Founded in 1998, GW is a biopharmaceutical comp...

    Filing Type:    PU
    Trevi Therapeutics, Inc.

    Trevi Therapeutics, Inc.

    We are developing nalbuphine ER to treat serious neurologically mediated condition...

    We are developing nalbuphine ER to treat seriou...

    Filing Type:    PU
    Stemline Therapeutics, Inc.

    Stemline Therapeutics, Inc.

    Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focuse...

    Stemline Therapeutics, Inc. is a commercial-sta...

    Filing Type:    PU
    Karyopharm Therapeutics Inc.

    Karyopharm Therapeutics Inc.

    Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on ...

    Karyopharm Therapeutics is an innovation-driven...

    Filing Type:    PU
    Ourotech, Inc.

    Ourotech, Inc.

    A patient that is diagnosed with cancer today will have a genetic screen on their ...

    A patient that is diagnosed with cancer today w...

    Fundraising Status:    SD
    Filing Type:    CF
    Dynavax Technologies Corporation

    Dynavax Technologies Corporation

    Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...

    Dynavax Technologies Corporation (Nasdaq: DVAX)...

    Filing Type:    PU
    Galapagos NV

    Galapagos NV

    Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, ...

    Galapagos develops therapies with proprietary, ...

    Filing Type:    PU
    Phormed Inc

    Phormed Inc

    PhorMed is a clinical stage biopharmaceutical company located in Beverly Hills Cal...

    PhorMed is a clinical stage biopharmaceutical c...

    Amount Raised:    $128,700.00
    Fundraising Status:    EC
    Filing Type:    CF
    ©2026 National Investor Network. All Rights Reserved.